GSK PLC closed 26.98% short of its 52-week high of £18.24, which the company reached on May 16th.

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...

GSK has shifted towards a global marketing ... While the new CEO has made some high-profile changes to the company’s management team, there have been some changes to the way the company ...

DUBLIN--(BUSINESS WIRE)--The "Enterprise Tech Ecosystem Series: GSK plc 2024" company profile has been added to ResearchAndMarkets.com's offering. The report provides insights into company's tech ...

The company’s regulatory application ... The studies confirmed that the vaccine has a safety profile consistent with the licensed meningococcal vaccines of GSK. The integration of the MenABCWY ...

GSK (LON:GSK – Get Free Report)‘s stock had its “underweight” rating reaffirmed by equities research analysts at JPMorgan ...

The firm owned 20,765 shares of the pharmaceutical company’s stock after selling 5,040 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in GSK were worth $702,000 as of its ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...